20/20 Biolabs is trading at $0.21, down 9.78%, with no confirmed company-specific explanation for the decline. - On November 5, the company issued a reminder about its December 9 special meeting, which includes a proposed reverse-split authorization intended to help regain Nasdaq’s $1.00 minimum-bid-price compliance; the announcement did not link it to the stock move. - Broader U.S. markets were sharply lower, while biotech was reported higher.